James B. DuHadaway

7.7k total citations · 2 hit papers
75 papers, 6.2k citations indexed

About

James B. DuHadaway is a scholar working on Molecular Biology, Biological Psychiatry and Immunology. According to data from OpenAlex, James B. DuHadaway has authored 75 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 33 papers in Biological Psychiatry and 21 papers in Immunology. Recurrent topics in James B. DuHadaway's work include Tryptophan and brain disorders (33 papers), Neuroinflammation and Neurodegeneration Mechanisms (10 papers) and Stress Responses and Cortisol (10 papers). James B. DuHadaway is often cited by papers focused on Tryptophan and brain disorders (33 papers), Neuroinflammation and Neurodegeneration Mechanisms (10 papers) and Stress Responses and Cortisol (10 papers). James B. DuHadaway collaborates with scholars based in United States, Germany and Slovakia. James B. DuHadaway's co-authors include George C. Prendergast, Alexander J. Muller, Erika Sutanto‐Ward, Preston S. Donover, Richard Metz, William P. Malachowski, David H. Munn, Lisa D. Laury‐Kleintop, Andrew L. Mellor and Laura Mandik‐Nayak and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

James B. DuHadaway

73 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

2005 873 citations Alexander J. Muller, James B. DuHadaway et al. profile →
Discovery of IDO1 Inhibitors: From Bench to Bedside

2017 428 citations George C. Prendergast, William P. Malachowski et al. Cancer Research profile →

Peers

James B. DuHadaway

IMMUN

ONCOL

Christiane A. Opitz Germany

Vincent Stroobant Belgium

Richard Metz United States

Luc Pilotte Belgium

Martina Ott United States

Claudia Volpi Italy

Gillian Mackay United Kingdom

Simon Scharpé Belgium

Lak Shin Jeong South Korea

Jun Wei China

Christiane A. Opitz Germany

James B. DuHadaway

1.9k ×0.6

2.5k ×1.0

1.3k ×0.7

IMMUN

648 ×0.6

755 ×0.7

ONCOL

Citations per year, relative to James B. DuHadaway James B. DuHadaway (= 1×) peers Christiane A. Opitz

Countries citing papers authored by James B. DuHadaway

Since Specialization

Citations

This map shows the geographic impact of James B. DuHadaway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. DuHadaway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. DuHadaway more than expected).

Fields of papers citing papers by James B. DuHadaway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James B. DuHadaway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. DuHadaway. The network helps show where James B. DuHadaway may publish in the future.

Co-authorship network of co-authors of James B. DuHadaway

This figure shows the co-authorship network connecting the top 25 collaborators of James B. DuHadaway. A scholar is included among the top collaborators of James B. DuHadaway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. DuHadaway. James B. DuHadaway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dey, Souvik, James B. DuHadaway, Erika Sutanto‐Ward, et al.. (2025). Neovascular pruning by IDO1 inhibitors can potentiate immunogenic cytotoxicity of ischemia-targeted agents to synergistically enhance anti-PD-1 responsiveness. Journal for ImmunoTherapy of Cancer. 13(5). e011398–e011398. 1 indexed citations

Chapellier, Marion, Evelina Martinenaite, Shamaila Munir Ahmad, et al.. (2024). Abstract 4094: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models. Cancer Research. 84(6_Supplement). 4094–4094. 1 indexed citations

Dey, Souvik, Arpita Mondal, James B. DuHadaway, et al.. (2021). IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research. 9(5). 514–528. 24 indexed citations

Nevler, Avinoam, Alexander J. Muller, Erika Sutanto‐Ward, et al.. (2018). Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS -Driven Sporadic Pancreatic Cancers. Clinical Cancer Research. 25(2). 724–734. 41 indexed citations

DuHadaway, James B., Khoa Pham, Ariel Lewis-Ballester, et al.. (2018). Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry. 162. 455–464. 42 indexed citations

Merlo, Lauren M.F., James B. DuHadaway, Elizabeth Pigott, et al.. (2017). Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clinical Immunology. 179. 8–16. 37 indexed citations

Pigott, Elizabeth, James B. DuHadaway, Alexander J. Muller, et al.. (2014). 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity. 47(6). 409–418. 19 indexed citations

Leoni, Giovanna, Yanru Wang, Peter P. Pham, et al.. (2013). The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Developmental Biology. 382(1). 160–171. 24 indexed citations

Smith, Courtney, Mee Young Chang, Katherine H. Parker, et al.. (2012). IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discovery. 2(8). 722–735. 260 indexed citations

10.

Kazerounian, Shiva, Damien Gerald, Minzhou Huang, et al.. (2012). RhoB Differentially Controls Akt Function in Tumor Cells and Stromal Endothelial Cells during Breast Tumorigenesis. Cancer Research. 73(1). 50–61. 40 indexed citations

11.

Huang, Minzhou, et al.. (2011). RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. Journal of Cellular Biochemistry. 112(6). 1572–1584. 32 indexed citations

12.

Divanovic, Senad, Nancy Sawtell, Aurélien Trompette, et al.. (2011). Opposing Biological Functions of Tryptophan Catabolizing Enzymes During Intracellular Infection. The Journal of Infectious Diseases. 205(1). 152–161. 89 indexed citations

13.

Muller, Alexander J., et al.. (2010). Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate. Cancer Research. 70(5). 1845–1853. 52 indexed citations

14.

Metz, Richard, James B. DuHadaway, Sonja Rust, et al.. (2010). Zinc Protoporphyrin IX Stimulates Tumor Immunity by Disrupting the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase. Molecular Cancer Therapeutics. 9(6). 1864–1871. 27 indexed citations

15.

Ramalingam, Arivudainambi, James B. DuHadaway, Erika Sutanto‐Ward, et al.. (2008). Bin3 Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. Cancer Research. 68(6). 1683–1690. 23 indexed citations

16.

Muller, Alexander J., Madhav Sharma, James B. DuHadaway, et al.. (2007). Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research. 67(2). 792–801. 467 indexed citations

17.

Metz, Richard, James B. DuHadaway, Uma Kamasani, et al.. (2007). Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound d -1-Methyl-Tryptophan. Cancer Research. 67(15). 7082–7087. 387 indexed citations

18.

Chang, Mee Young, Janette Boulden, Erika Sutanto‐Ward, et al.. (2007). Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression. Cancer Research. 67(1). 100–107. 36 indexed citations

19.

Muller, Alexander J., James B. DuHadaway, Tinku Banerjee, et al.. (2007). Brassinin compounds exhibit anti-cancer activity mediated through inhibition of the immunotolerogenic enzyme Indoleamine 2,3-dioxygenase (IDO). Cancer Research. 67. 224–224. 1 indexed citations

20.

Muller, Alexander J., James B. DuHadaway, Erika Sutanto‐Ward, Preston S. Donover, & George C. Prendergast. (2005). Transcriptional control of IDO by the cancer suppression gene Bin1, a key mechanism for restraining tumor immune escape. Cancer Research. 65. 1255–1255. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact